Please see our Legal Disclaimer regarding information provided on our corporate website.

Legal Disclaimer – Please Read

This website (the “Website”) of general background information about Abattis Bioceuticals Corp. (“Abattis”) activities is current as of September 2017. It is in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate.

This Website does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities of Abattis, nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever by or with Abattis. Recipients of this Website who are considering acquiring securities of Abattis are reminded that any such purchase or subscription must not be made on the basis of the information contained in this Website but are referred to the entire body of publicly disclosed information regarding Abattis.

The information contained in this Website is derived solely from management of Abattis and otherwise publicly available information concerning Abattis and does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in Abattis. The information has not been independently verified and is subject to material updating, revision and further amendment, and is qualified entirely by reference to Abattis’ publicly disclosed information. No representation or warranty, express or implied, is made or given by or on behalf of Abattis or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Website and no responsibility or liability is accepted by any person for such information or opinions. Abattis does not undertake or agree to update this Website or to correct any inaccuracies in, or omissions from, this Website that may become apparent, except as required by applicable securities laws. No person has been authorized to give any information or make any representation other than those contained in this Website and, if given and/or made, such information or representation must not be relied upon as having been so authorized. The information and opinions contained in this Website are provided as at the date of this Website. The contents of this Website are not to be construed as legal, financial or tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice. Certain statements in this Website may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of applicable securities laws. Often but not always, forward-looking information can be identified by the use of words such as “anticipate”, “believe”, “expect”, “project”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “might”, “target”, “plan” and other similar expressions or variations (including negative variations) of such words and phrases. Forward-looking information contained in this Website is based on certain assumptions examples and statements regarding: (I) Financial projections; (II) Expected growth in cannabis production, demand and user base; (III) expected growth of cannabis derivative products; (IV) That vergence is expected to be the main distribution line for northern vine products; (V) Northern Vine’s expected ability to soon be able to test for pesticides; (VI) Third party testing becoming standard regulatory policy; (VII) That vergence is proposed to be a main north american and international sales arm for cbd manufacturers out of china; (VIII) The terms of vergence’s MOU; (IX) The value of Canadian exports to China and Chinese demand; and (X) Abattis’ proposed social media campaign and educational events.

Forward looking information contained in this website is based on certain assumptions regarding (I) Abattis ability to obtain any necessary financing on acceptable terms or at all; (II) timing and amount of capital expenditures; (III) management’s ability to implement the business plan; (IV) the current and expected regulatory climate for cannabis; and (V) general economic and financial market conditions. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including: (I) changes in general economic or market conditions; (II) abattis’ ability to effectively implement its strategies and business plan; (III) a change in demand for cannabis products; (IV) changes to proposed distribution plans; (V) the ability to retain services of senior management and key employees; (VI) the ability to maintain compliance with all government regulations and obtain and/or maintain applicable Health Canada licenses ; (VII) competition from other cannabis producers and testing facilities; (VIII) litigation risk; (IX) failure by vergence to enter into definitive agreements with respect to the MOU; (X) failure of securing counter parties to material contracts to perform their obligations; (XI) political risk relating to the legalization and other regulation of cannabis; and (XII) other factors beyond Abattis’ control. These risks, as well as risks that management cannot currently anticipate, could cause Abattis’ actual results or levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by the forward-looking statements in this website.

Abattis disclaims any obligation to update any forward-looking information, whether as a result of new information, future events or otherwise except as required by applicable securities laws. Readers should refer to the risk factors outlined in Abattis reports filed publicly on Sedar at